- Home
- CNR vs TLX Comparison
CNR vs TLX Comparison
Compare CNR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- TLX
- Stock Information
- Founded
- CNR 1864
- TLX 2015
- Country
- CNR United States
- TLX Australia
- Employees
- CNR N/A
- TLX N/A
- Industry
- CNR Coal Mining
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- TLX Health Care
- Exchange
- CNR Nasdaq
- TLX Nasdaq
- Market Cap
- CNR 4.4B
- TLX 3.6B
- IPO Year
- CNR N/A
- TLX N/A
- Fundamental
- Price
- CNR $83.48
- TLX $10.80
- Analyst Decision
- CNR Strong Buy
- TLX Strong Buy
- Analyst Count
- CNR 5
- TLX 4
- Target Price
- CNR $110.10
- TLX $21.00
- AVG Volume (30 Days)
- CNR 1.1M
- TLX 118.4K
- Earning Date
- CNR 11-06-2025
- TLX 01-01-0001
- Dividend Yield
- CNR 0.48%
- TLX N/A
- EPS Growth
- CNR N/A
- TLX N/A
- EPS
- CNR 0.51
- TLX 0.04
- Revenue
- CNR $3,275,589,000.00
- TLX $664,225,558.00
- Revenue This Year
- CNR $93.87
- TLX N/A
- Revenue Next Year
- CNR $8.40
- TLX N/A
- P/E Ratio
- CNR $163.00
- TLX $335.52
- Revenue Growth
- CNR 47.13
- TLX 55.35
- 52 Week Low
- CNR $58.19
- TLX $8.93
- 52 Week High
- CNR $134.59
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- CNR 44.73
- TLX 55.71
- Support Level
- CNR $82.39
- TLX $10.72
- Resistance Level
- CNR $93.07
- TLX $11.00
- Average True Range (ATR)
- CNR 4.90
- TLX 0.28
- MACD
- CNR -1.94
- TLX 0.10
- Stochastic Oscillator
- CNR 5.31
- TLX 73.12
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.